Furthermore, treatment of ovarian tumors with EZH2 and DNMT1 inhibitors increased the efficacy of tumor-associated antigen-specific CD8+ T cells in response to inhibition of the PD-1: PD-L1 checkpoint [91]. Here, DNMT1 is linked to ovarian neoplasm.